Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Each RBP-01 dose consists of a 5 µL intravitreal injection conjugating 250 µg of sotrastaurin.”In the company’s words, NCT07747935 on ClinicalTrials.gov
- Tested for
- Uveal Melanoma
- Main trialPhase 1/2
- “Neoadjuvant RBP-01 in patients with primary uveal melanoma.”In the company’s words, NCT07747935 on ClinicalTrials.gov
Other drugs for Uveal Melanoma
- DarovasertibIDEAYA Biosciences · Phase 3
- AU-011Aura Biosciences · Phase 3
- RP2Replimune, Inc. · Phase 2/3
- Melphalan/HDSDelcath Systems Inc. · Phase 3
- EB-DTKN-401Beijing Biotech · Phase 1/2
- DYP688Novartis · Phase 1/2
Coming up1
- 1 Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 1 Apr 2028 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026